Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

MTHFD2 Inhibitors for treatment of AML

Reference number
Coordinator Karolinska Institutet - Science for Life Laboratory
Funding from Vinnova SEK 950 000
Project duration June 2018 - May 2019
Status Completed

Purpose and goal

The project has reached the overarching objectives of progressing to TRL4 and nomination of a Candidate Drug for further preclinical development. Moreover, all milestones for advancing the project beyond Stop/Go decisions were successfully met, as well as the majority of deliverables defined for the Work Packages.

Expected results and effects

The project has advanced from Lead Optimization (TLR3) to Preclinical Development (TLR4) within a year, thus cost-effectively de-risking the therapeutic concept and thereby significantly increasing the commercial potential. Furthermore, the underlying molecular mechanism behind the cancer-specific phenotype induced by MTHFD2i has been unraveled.

Planned approach and implementation

The project has been able to reach the objectives by (a) from the outset defining productive work packages with realistic timelines and tangible deliverables; (b) effective collaborations between academia, clinicians and industry

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 January 2019

Reference number 2018-00257

Page statistics